The Egyptian Journal of Medical Human Genetics xxx (2017) xxx–xxx

HOSTED BY

Contents lists available at ScienceDirect

The Egyptian Journal of Medical Human Genetics

journal homepage: www.sciencedirect.com



Original article

Association of proinflammatory cytokine IL-20 gene polymorphism with psoriasis in north Indian population

Aadil Wani [a,c], Bashir Ahmad Ganai [d], Tahseena Akhtar [a], Tarun Narang [b], Rajinder Kaur [a,*]

[a] Department of Human Genetics, Punjabi University, Patiala, Punjab, India
[b] Department of Dermatology, Venerology and Leprology Post Graduate Institute of Medical Education and Research Chandigarh, India
[c] Department of Biochemistry University of Kashmir Srinagar, Jammu and Kashmir, India
[d] Centre of Research and Development (CORD) University of Kashmir Srinagar, Jammu and Kashmir, India

ARTICLE INFO

Article history:
Received 11 August 2017
Accepted 11 September 2017
Available online xxxx

Keywords:
Cytokine
Polymorphism
IL-20
ELISA
Psoriasis

ABSTRACT

Background: IL-20 plays an important role in the inflammatory and hyperproliferative dermatosis of psoriasis.
Aim: The aim of the study was to determine whether the IL-20 gene polymorphism, haplotype and serum level confer pathogenesis of psoriasis.
Subjects and methods: 200 psoriatic patients and 200 controls were genotyped for four IL-20 polymorphic sites by polymerase chain reaction. Serum levels of IL-20 were measured by ELISA.
Results: Our results demonstrated that polymorphism of IL-120 −1380 A/G (adjusted* OR 5.52; (95% CI = 2.43–12.55) was found to be in association with increased risk of psoriasis while as IL-20–1462 G/A (adjusted* OR = 0.11 95; (95% CI = 0.03–0.34) was found to be in association with decreased risk of psoriasis and IL-20–1053 G/T adjusted* OR 1.99; (95% CI = 0.86–4.64), IL-20–3978 T/C(adjusted* OR = 12.87; (95% CI = 0.97–79.54) polymorphism does not show any significant association with the risk of psoriasis. HT4 TG haplotype is associated with decreased risk of psoriasis. Serum IL-20 level significantly increases in patients, as compared to controls with non-significant correlation between serum IL-20 and psoriasis severity.
Conclusion: These findings suggest that IL-20 polymorphism have significant role towards the susceptibility of psoriasis in north Indian population. Evaluating the role of IL-20 cytokine in pathogenesis of psoriasis will prove helpful for the development of psoriasis management.

1. Introduction

Psoriasis is a polygenic cutaneous disorder characterized by hyperproliferation, differentiation of keratinocytes, and influx of immune cells into the epidermis [1,2]. The prevalence of psoriasis has recently been inferred as varying from 0.44 to 2.80% in india [3]. IL-20 belongs to the IL-10 cytokine family, which also includes IL-19, IL-22, IL-24, and IL-26 [2,4]. IL-20 is secreted by immune cells and activated epithelial cells like keratinocytes [5]. The function of IL-20 might therefore mediate a crosstalk between epithelial cells and tissue-infiltrating immune cells under inflammatory conditions [6]. IL 20 binds to the receptor expressed on keratinocytes [7]. The exposure of the cells to IL-20 induces STAT3 activation which appears to be the initiator of the signal in the epidermal keratinocytes, leading to the development of psoriatic lesion [6,8]. There is strong evidence that interleukin-20 (IL-20) has a role in the pathogenesis of cutaneous inflammation and in psoriasis [9,10]. Genes encoding for the IL-10, IL-19, IL-20 and IL 24 are found within a 200 kb region of chromosome 1, and all comprise of IL-10 family cytokine cluster [2,10]. Earlier studies have presented evidence for an association between IL-10 SNPs with susceptibility to a numerous autoimmune, infectious and malignant, diseases [11]. Until now, few studies have confirmed that the IL-20 SNPs contribute to the susceptibility towards psoriasis [12–14]. In the view of the above findings, IL-20 appears to be the candidate gene for psoriasis understanding. The present study was designed to investigate whether the IL-20 polymorphism, haplotype analysis and serum levels may be risk factors for the development of psoriasis in north India. To our knowledge no polymorphism study of IL-20 gene has been reported till now in north Indian population.

Peer review under responsibility of Ain Shams University.
* Corresponding author.
E-mail address: rajinderkaur@pbi.ac.in (R. Kaur).

http://dx.doi.org/10.1016/j.ejmhg.2017.09.002
1110-8630/

2. Materials and methods

2.1. Subject recruitment

This hospital based case-control study was conducted after approval by the ethical committee. The subjects were included only after they willingly decided to become part of the study, and filled the consent form. This study was conducted over the period of fifteen months starting from September 2014 up to November 2015 and includes 200 clinically diagnosed psoriatic patients. The inclusion of psoriasis patients was based on the proper diagnosis which included PASI calculation. Gender, age (±7 years) and geographically matched healthy subjects were included as controls in the study.

2.2. PASI calculation

Psoriasis Area and Severity Index (PASI) is widely used tool for the measurement of severity of psoriasis. PASI score was calculated as described by Langle et al. [15]. The more value of PASI score represents a greater degree of psoriatic severity [16].

2.3. Blood sampling

Five ml of venous blood was taken after taking consent from each subject and was divided into two portions. 2 ml was taken in sterile EDTA coated vials for Genomic DNA Extraction and the remaining was centrifuged at 4000 rpm for 5 min. Serum separated was stored at −80 °C till analysis.

2.4. Genomic DNA extraction

Genomic DNA was isolated from the blood samples by using Phenol-Chloroform method [17] and the isolated DNA was stored at −20 °C for future use.

2.5. Genotyping of IL-20

Novel tetra-primer ARMS-PCR method was applied for genotyping of polymorphisms of IL-20 as prescribed by Kingo et al., [12] Each PCR reaction was carried out in a total volume of 10 μl containing 100 ng of template DNA, 20 pmol of each inner primer, 20 pmol of each outer primer, optimized concentrations of master mix. To increase the specificity of a PCR reaction we applied touchdown cycles: initial denaturation at 95 °C for 2 min followed by 10 cycles of 1 min denaturation at 95 °C, annealing at 10 °C higher than annealing temperature for 1 min (decreasing by 1 °C per cycle) and extension at 72 °C for 1 min.

3. Results

Two hundred confirmed psoriatic cases and an equal number of healthy, age and gender matched controls were recruited in this study. After analyzing the data out of 200 cases recruited in the present study, 130 (65%) were males and 70 (35%) were females. It was found that age ranged from 18 to 70 years with mean 38.61 ± 13.713 in the psoriatic patients while in controls, age ranged from 19 to 65 years with mean value of 36.695 ± 11.4765. Thirty-two (16%) psoriatic patients show the positive family history for psoriasis. Of all the regions majority of cases numbering 57.5% were from rural areas while as 42.5% are from urban areas. Body Mass Index (BMI) of psoriatic patients and controls was 26.94 ± 4.17 Kg/m^2 and 24.80 ± 4.28 kg/m^2 respectively. The mean value of PASI score for clinical assessment in psoriatic patients was (10.654 ± 9.09) (Table 1).

The allele frequencies and genotype frequencies of IL20 1053T/G(rs2981572), IL 20-1380A/G (rs2981573), IL20-1462G/A (rs2232360) and IL 3978T/C(rs1518108) SNPs in patients and controls are summarized in Tables 2–5 respectively. Genotype distributions for the four analyzed IL-20 gene polymorphisms had no deviation from Hardy–Weinberg equilibrium. The minor T allele and TT genotype frequency at position −1053 (rs2981572), was found higher in cases as compared to that of controls (OR = 1.091; 95% CI = 0.816–1.458, adjusted* OR = 1.99; 95% CI = 0.86–4.64 respectively). The difference came out to be statistically non-significant which confirms that −1053TT genotype is not associated with risk of psoriasis. Constructed dominant model do not show any association with the risk of psoriasis. However overdominant (adjusted* OR = 2.52; 95% CI = 1.13–5.63) shows association of genotypes as a risk factor for psoriasis and recessive models (adjusted* OR = 0.57; 95% CI = 0.36–0.91) plays a protective role for psoriasis. Representative gel picture of IL-20-1053 T/G (rs2981572) gene polymorphism by ARMS PCR as shown in Fig. 1. The frequency of minor G allele and GG genotype at position −1380 (rs2981573) was found higher in cases as compared to that of controls (OR = 3.44; 95% CI = 2.26–5.24, adjusted* OR 5.52; 95% CI = 2.43–12.55 respectively) which confirms that −1380A/G polymorphism is associated with increased risk of psoriasis. The dominant (adjusted* OR = 3.43; 95% CI = 1.88–6.28) and recessive (Adjusted* OR = 5.52; (95% CI = 2.31–11.83) models show association of genotypes as a risk factor for psoriasis. However no such association has been seen in case of over dominant model. Representative gel picture of IL-20-1380 A/G (rs2981573) gene polymorphism by ARMS PCR as shown in Fig. 2. The frequency of minor G allele and GG genotype at position −1462 (rs2232360) was found higher in controls as compared to that of cases (OR = 0.681; 95% CI = 0.51–0.90, adjusted* OR = 0.11 95; 95% CI = 0.03–0.34 respectively). The polymorphism of IL-20-1462A/G was found to be in association with decreased risk of psoriasis. The dominant (adjusted* OR = 0.46; 95% CI = 0.24–0.86) and recessive (adjusted*

Table 1
Characteristics of study group.

Characteristics			Cases (%)	Controls (%)
Age: X ± SD			38.61 ± 13.71 Years	36.695 ± 11.47 Year
Sex	Male		130 (65.00%)	130 (65.00%)
	Female		70 (35.00%)	70 (35.00%)
Family History of psoriasis			32(16.00%)	–
Disease duration ± SD			9.88 ± 8.19 Years	
Dwelling		Rural	115 (57.50%)	115 (57.50%)
		Urban	85 (42.50%)	85 (42.50%)
BMI(kg/m^2)X ± SD			26.94 ± 4.17	24.80 ± 4.28
PASI: X ± SD			10.654 ± 9.09	–
PDI: X ± SD			19.11 ± 6.1081	

Please cite this article in press as: Wani A et al. . Egypt J Med Hum Genet (2017), http://dx.doi.org/10.1016/j.ejmhg.2017.09.002